The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
38 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $19,589,340 in first-year total cost, median $326,455.
Most frequent study sections
- Special Emphasis Panel[ZDA1 SAI-S (A1)]13
- Special Emphasis Panel[ZDA1 SUY-S (J1)]12
- Special Emphasis Panel[ZDA1 GXM-A (J1)]8
- Special Emphasis Panel[ZDA1 SUY-S (A1)]5
Most frequent institutions
- AUTONOMOUS HEALTHCARE, INC.2
- INSTANOSIS, INC.2
- ACTIOX LLC1
- AFASCI, INC.1
- AKINA, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | A Rapid, Sensitive and Instrument-free Oral Fluid Fentanyl Test1R44DA061963-01 | WANG, PINGXIA, XIAOFENG | INSTANOSIS, INC., DE | $1,576,513 | ZDA1 |
| 2025 | Phase 0/1b Clinical Trial of Novel Therapeutic Agent MT-110 for the Reduction of Methamphetamine Use - Part 21R44DA063266-01 | YOUNG, ERICA J | MYOSIN THERAPEUTICS INC., FL | $1,496,586 | ZDA1 |
| 2025 | Noncontact Monitoring for the Detection of Opioid-Induced Respiratory Depression2R44DA058470-02 | GHOLAMI, BEHNOOD | AUTONOMOUS HEALTHCARE, INC., CA | $1,157,858 | ZDA1 |
| 2025 | Wireless Wearable with AI Analytics for Monitoring Neonatal Abstinence Syndrome (NAS)1R44DA060640-01A1 | SHARAREH, SHIVA | REKOVAR INC., CA | $411,800 | ZDA1 |
| 2025 | Building a Contextually Triggered Just-in-Time Intervention for Opioid UseDisorder: Stakeholder Evaluation and User Centered Design1R43DA060641-01A1 | ALLEN, NICHOLAS B | KSANA HEALTH, INC., OR | $406,451 | ZDA1 |
| 2025 | Advancing FGF13-Nav1.6 modulators to normalize Nucleus Accumbens activity for Cocaine Use Disorder1R43DA063261-01 | LIJFFIJT, MARIJN | IONTX INC., TX | $400,000 | ZDA1 |
| 2025 | User-Centric Development of a Detection Module for a Closed-Loop Solution to Opioid Overdose1R43DA063255-01 | LE, VYLEE, HYOWON | RESCUE BIOMEDICAL, LLC, IN | $399,715 | ZDA1 |
| 2025 | Developing high-precision epigenetic therapeutics for opioid use disorder1R43DA063250-01 | CHOI, SOONGANG | BOSTON INTERACTOME LLC, MA | $398,137 | ZDA1 |
| 2025 | Identification of therapeutic molecules to treat amphetamine use disorders using our DNA-encoded library (DEL) technology1R43DA061909-01 | FLAJOLET, MARC | JILLION THERAPEUTICS INC., NY | $398,093 | ZDA1 |
| 2025 | Rapid Fingerstick Diagnostics for Opioid and Stimulant Use Disorders1R43DA063260-01 | ERVIN, ERIC | ELECTRONIC BIOSCIENCES, INC., CA | $386,452 | ZDA1 |
| 2025 | COPA: A clinical program to evaluate benefits of a hand-held, automated, personalized oral liquid dispensing system for take-home methadone medication management for patients with opioid use disorder.1R44DA061908-01A1 | TIMBERLAKE, JOHN | BERKSHIRE BIOMEDICAL CORPORATION, TX | $326,410 | ZDA1 |
| 2025 | Etimizol for reversal of Xylazine-fentanyl respiratory depression1R43DA061953-01 | GOMTSIAN, ARTOUR | SYNVENTA, LLC, AZ | $277,389 | ZDA1 |
| 2024 | A Novel Reversal Agent for Treatment of Overdose from the Combination of Fentanyl and Xylazine2R44DA056272-02 | LI, XINHUA | CLEAR SCIENTIFIC, LLC, MA | $1,462,687 | ZDA1 |
| 2024 | Decentralized clinical trial of contingency management digital therapeutic to treat stimulant use disorder1R44DA059519-01 | GASTFRIEND, DAVID RRASH, CARLA J | DYNAMICARE HEALTH, INC., MA | $1,076,018 | ZDA1 |
| 2024 | Development of small molecule therapeutics for mitigating opioid withdrawal syndrome2R44DA053844-02 | LABED, SID AHMED | EVODENOVO, INC., MA | $880,957 | ZDA1 |
| 2024 | Rapid, Instrument-free and High Sensitivity Over-the-counter Urine Fentanyl Testing1R44DA060647-01 | WANG, PINGXIA, XIAOFENG | INSTANOSIS, INC., DE | $403,636 | ZDA1 |
| 2024 | Software as a Medical Device for detecting opioid use through voice.1R43DA060696-01 | SEIILOVA-OLSON, RIMA | TENVOS INC., CA | $400,000 | ZDA1 |
| 2024 | Developing a wearable medical device to detect opioid overdose1R44DA060643-01 | HOLDEN, BRADFORD A | RESILIENT LIFESCIENCE, INC., PA | $399,589 | ZDA1 |
| 2024 | Investigation of a Novel PDE4B Inhibitor for Stimulant Use Disorder1R43DA060646-01 | LACKOVIC, JACOB EDWARDVARADHACHARY, ATUL | FANNIN PARTNERS, LLC, TX | $320,000 | ZDA1 |
| 2024 | Stimulant Use Recovery Via Immersive Virtual Environments (SURVIVE)1R43DA059490-01 | BRACKEN, BETHANY K | CHARLES RIVER ANALYTICS, INC., MA | $319,988 | ZDA1 |
| 2024 | Development of a Machine Learning Algorithm to Detect Opioid Withdrawal and Cravings to Increase Treatment Retention1R43DA059448-01 | KHODAPARAST, NAVID | SPARK BIOMEDICAL INC, TX | $318,875 | ZDA1 |
| 2024 | Mechanism and Efficacy of a Novel Opioid Adjuvant1R43DA059522-01 | MEYN, MALCOLM A | AMALGENT THERAPEUTICS, INC., NC | $220,668 | ZDA1 |
| 2023 | IND-enabling development of a long-duration antagonist to treat opioid overdose2R44DA050386-02 | ZANA, LAWRENCE J | CONSEGNA PHARMA, INC., PA | $1,330,781 | ZDA1 |
| 2023 | Cue-induced drug craving monitoring for opioid use disorder with visual evoked potentials1R44DA059517-01 | BURWELL, SCOTT | NEUROTYPE INC., MN | $328,963 | ZDA1 |
| 2023 | Modular Virtual Reality Therapeutic for Opioid and Stimulant Use Disorders1R44DA059475-01 | WASHBURN, MICHELLE (MICKI) EZIEMBA, PAUL | INNATEVR, LLC, MI | $326,500 | ZDA1 |
| 2023 | Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression1R44DA059491-01 | BOSAK, MAGDALENA KIRLAKOVSKY | RTM VITAL SIGNS, LLC, PA | $325,601 | ZDA1 |
| 2023 | Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy1R43DA058430-01 | PLUMP, STEVEN R.SADHASIVAM, SENTHILKUMAR | OPALGENIX, INC., IN | $325,239 | ZDA1 |
| 2023 | Noncontact Remote Monitoring for the Detection of Opioid-Induced Respiratory Depression1R43DA058470-01 | GHOLAMI, BEHNOOD | AUTONOMOUS HEALTHCARE, INC., CA | $325,001 | ZDA1 |
| 2023 | Injectable 3-month buprenorphine PLGA microparticle formulation1R43DA058410-01 | PARK, HAESUN | AKINA, INC., IN | $320,000 | ZDA1 |
| 2023 | Novel formulation technology for the sustained release naloxone to improve outcomes in the management of opioid overdose1R43DA058477-01A1 | TORRES LUNA, CESAR | LYNTHERA CORPORATION, PA | $320,000 | ZDA1 |
| 2023 | Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder1R44DA058467-01 | GREENBERG, MILTON L | VIVREON BIOSCIENCES, LLC, CA | $319,991 | ZDA1 |
| 2023 | BoostPrime, A Novel Digital Therapeutic for Craving Mitigation in OUD1R44DA058531-01 | PATEL, SALIL | NXTECH INC, TX | $319,915 | ZDA1 |
| 2023 | A wearable device for continuous monitoring of methadone1R43DA059516-01 | TEHRANI, FARSHAD | ACTIOX LLC, CA | $319,754 | ZDA1 |
| 2023 | Development of the OpiAID strength band platform1R44DA058474-01 | MACQUEEN, DAVID ALDERSONREESER, DAVIDWASHINGTON, WENDY DONLIN | OPIAID, INC., NC | $319,589 | ZDA1 |
| 2023 | Developing a novel treatment of cocaine use disorder using an IND dual inhibitor of Cav3 channel and soluble epoxide hydrolase1R43DA059524-01 | XIE, XINMIN SIMON | AFASCI, INC., CA | $319,547 | ZDA1 |
| 2023 | Development of an AI-empowered device that utilizes multimodal data-visualization to aid in the diagnosis, and treatment, of OUD1R44DA058431-01 | OAKLEY, DAVID | WAVI COMPANY, CO | $319,080 | ZDA1 |
| 2023 | Therapeutic Monitoring System (TMS)1R44DA059523-01 | SCHMIDLE, PATRIK | CARI HEALTH, INC., CA | $318,257 | ZDA1 |
| 2023 | Development of compound RUEC2-118, a novel partial GABAAR positive modulator, a fast-acting treatment for general anxiety and panic disorder, to prevent opioid and benzodiazepine overdose fatalities.1R41DA058472-01 | CARRY, EILEEN | ZENA THERAPEUTICS INC., NJ | $313,300 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.